Mirabegron is the first drug in a new class of oral therapy for overactive 
bladder (OAB). It is a beta-3 adrenergic agonist, a class of drugs for the first 
time used for the treatment of urination disorders. Recently, following many 
years of rigorous multicenter randomized trials mirabegron has been approved for 
use in Europe and North America. The clinical indication for mirabegron is 
overactive bladder with symptoms of urge urinary incontinence, urgency, and 
urinary frequency and other storage symptoms in both men and women. Mirabegron 
is used in primary patients, or in patients who previously were unsuccessfully 
treated with anticholinergics. The drug has a good safety profile and causes no 
side effects typical of anticholinergics.